Axillary Hyperhidrosis Drug Market Scope
Hyperhidrosis is excessive sweating that goes beyond what is physiologically necessary for thermoregulation and often causes social, emotional, and work-related impairments. This condition can be primary or secondary. Primary hyperhidrosis is idiopathic, bilaterally symmetrical, excessive sweating of the armpits, palms, soles of the feet, face, and less often the scalp or groin folds. Secondary hyperhidrosis can be focal or generalized and is caused by an underlying illness or the use of medication. The doctor can prescribe an antiperspirant with aluminum chloride (Drysol, Xerac Ac). Some of the oral medications block the chemicals that allow certain nerves to communicate with each other. This can reduce sweating in some people. In addition, some of the medications for depression can also reduce sweating. Treatment by the usage of botulinum toxin (myobloc, botox, others) temporarily helps in blocking the nerves that thereby cause sweating. The effects last for six to 12 months, and then the treatment must be repeated. This treatment can be painful and some people experience temporary muscle weakness in the area being treated.
The market study is being classified by Type (Prescription Antiperspirant, Nerve-blocking Medications, Antidepressants, Botulinum Toxin Injections and Others), by Application (Clinic, Hospital, Home Care and Others) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Axillary Hyperhidrosis Drug market throughout the predicted period.
Allergan Plc (Ireland), Brickell Biotech Inc. (United States), Dermira Inc. (United States), Dr. August Wolff GmbH & Co KG Arzneimittel (Germany), GlaxoSmithKline Plc (United Kingdom), TheraVida Inc. (United States), Revance Therapeutics, Inc. (United States) and Ulthera, Inc. (United States) are some of the key players profiled in the study.
AdvanceMarketAnalytics has segmented the market of Global Axillary Hyperhidrosis Drug market by Type, Application and Region.
On the basis of geography, the market of Axillary Hyperhidrosis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
First-line treatment of all primary focal hyperhidrosis, regardless of severity, is topical 20% aluminum chloride (Drysol). For craniofacial hyperhidrosis, topical 2% glycopyrrolate (compounded by a pharmacy) may be considered first-line treatment. It has shown a 96% success rate with minimal adverse effects (mild skin irritation) and can be applied once every two to three days. There are three devices registered with the U.S. Food and Drug Administration namely, RA Fischer MD-1a, RA Fischer MD-2, and Drionic. The procedure can be easily performed at home, and adverse effects (e.g., erythema, vesiculation, tingling) are typically mild and do not require cessation of the treatments. Also, there are several commercially available botulinum toxin preparations approved by the U.S. Food and Drug Administration that are available to physicians who are trained in this procedure. The most commonly used is onabotulinumtoxinA (Botox).
- Increasing Healthcare Spending and Demand for Drug Therapy
- Growth in the Trend of Setting up Of Well-Established Health Care Facilities in Developed Regions
- Growing Geriatric Population in Major Economies
- Increasing Awareness among People about Preventive Healthcare
- The Rise in Incidence Rates of Hyperhidrosis Disorder across the Globe
- R&D and Product Innovation
- The Rise in the Online Pharmacies
- Potential Growth From Emerging Countries
- Increasing Adoption of Western Life Style, Changing Health Care Infrastructure, And Ease in the Availability Of Therapeutic Drugs
- Stringent Government Rules and Regulation
- Side Effects Due to Axillary Hyperhidrosis Drug
- Availability of Substitutes
- Unawareness About the Disease and Treatment in the Developing Regions
Key Target AudienceManufacturers of Axillary Hyperhidrosis Drug, Suppliers and Distributors of Axillary Hyperhidrosis Drug, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase